Physician profile
Rakesh Kumar
NPI 1649427428
$4,435.35
in general payments reported to CMS, 2019-2025
33 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,974 · 2020: $93.15 · 2021: $30.73 · 2022: $355 · 2023: $483 · 2024: $770 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891 · Education: $91.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.29 |
| Education | $91.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $1,422.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $308.51 | 2022-2025 | |
| Travere Therapeutics, INC. | $299.61 | 2022-2025 | |
| Vifor Pharma, INC. | $239.29 | 2019-2024 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $226.64 | 2019-2025 | Rayaldee |
| Amgen INC. | $212.40 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $196.04 | 2019-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.80 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $166.07 | 2022-2025 | Velphoro, Velphoro |
| Horizon Therapeutics Plc | $148.74 | 2019-2023 | Krystexxa |
| Scpharmaceuticals INC. | $135.71 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $133.62 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $110.37 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $81.57 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $73.66 | 2023-2025 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56.31 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $48.95 | 2023-2025 | Rivfloza, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $45.63 | 2019-2025 | |
| Apellis Pharmaceuticals, INC. | $39.18 | 2025 | Empaveli |
| Daiichi Sankyo INC. | $35.98 | 2019-2023 | Injectafer |
| Cumberland Pharmaceuticals, INC. | $31.03 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $28.89 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $25.87 | 2023 | |
| Akebia Therapeutics INC | $25.51 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $24.55 | 2019 | |
| Shield Therapeutics INC | $21.22 | 2024 | |
| Merck Sharp & Dohme LLC | $19.90 | 2025 | Zerbaxa |
| Janssen Pharmaceuticals, INC | $19.20 | 2019 | |
| Glaxosmithkline, LLC. | $17.85 | 2025 | Benlysta |
| Takeda Pharmaceuticals U.S.A., INC. | $17.08 | 2023 | Gattex |
| Mallinckrodt Hospital Products INC. | $16.48 | 2024 | Acthar |
| Recordati_rare_diseases_inc. | $16.46 | 2025 | Cystadrops |
| Boston Scientific Corporation | $15.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.